Allogene Therapeutics
Hien Do has a diverse work experience history, with a focus on drug safety and compliance. They are currently working as an Associate Director of Drug Safety Operations and Compliance at Allogene Therapeutics since January 2023. Prior to this, Hien worked at Nektar Therapeutics as an Associate Director of Drug Safety Operations until November 2022. They also held roles at AbbVie, Pharmacyclics (an AbbVie Company), Onyx Pharmaceuticals, Affymax, Jazz Pharmaceuticals, and Pathologica, LLC, and SLIL Biomedical, Inc. in various drug safety and research positions. Hien's experience spans from managing case management and global case management to performing quality control reviews, data analysis, and participating in database management and upgrades. They have also worked as a Medical Doctor at the Medic Diagnostic Center in Ho Chi Minh City, Vietnam.
Hien Do has a certificate in Clinical Trials Design and Management from the University of California, Santa Cruz. Additionally, Hien Do obtained an M.D. degree, but the name of the school and the field of study during this period are unknown.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.